When Zhang Junjie was 17 he decided to protest outside his university about rules made by China's government. Within days he ...

When Carol Emery’s son, Colin, was 11 years old, he started to show signs of what she’d come to learn was paranoia — though ...

Could the largest market for the new schizophrenia drug xanomeline and trospium chloride (Cobenfy) be in Alzheimer's disease ...

In this episode, NAMI CEO Dan Gillison, Jr. is joined by Chief Medical Officer Dr. Ken Duckworth to explore why the language ...

Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company currently valued at $5.8 million and showing promising revenue growth of 62% over the last twelve months, announced the release of two ...

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Duke neuroscientist Kafui Dzirasa wants nothing less than to reengineer the brain’s electrical patterns to treat anxiety, ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Johnson & Johnson's $14.6bn acquisition of Intra-Cellular Therapies adds Caplyta and a robust pipeline targeting major ...

Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion. The deal includes Caplyta, a treatment for schizophrenia and bipolar depression, along with a pipeline focused on ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...